



**MEDIMETRIKS**  
PHARMACEUTICALS, INC.

Dermatology Excellence

# Medimetriks Highlights

---

- **Specialty pharma company targeting medical Dermatology**

- Established commercial operations with a Sales Force approaching 40 strong in key US markets

- Marketed brands for treatment of acne, rosacea, atopic dermatitis, fungal infections and nail dystrophy

- Integrated clinical drug development capabilities

- Development team has broad experience working with FDA and achieving NDA approvals, including Xepi™ (ozenoxacin cream), December 2017

- **Development pipeline: MM36 (Difamilast)**

- Novel topical, non-steroidal PDE4 inhibitor for atopic dermatitis and itch

- Demonstrated safety, efficacy and **rapid itch relief** in Phase 2 clinical trials
- Preparing for Phase 3 trials

# Business Overview

1

## Strong Existing Portfolio & Commercial Platform

- Existing portfolio of positive cash flow dermatology brands sold through national US sales force
- Commercial expertise in maximizing brand value in key medical dermatology markets
- Acquiring commercialized assets to leverage company infrastructure and commercial platform

2

## Development Expertise & Lifecycle Management

- Line extension development provides growth potential prior to MM36 launch
- Achieved FDA approval of Xepi™ (ozenoxacin) cream, a topical antibiotic for impetigo Dec. 2017

3

## MM36: Blockbuster Brand Launch

- Potential best in class treatment in the large, underserved US AD market
- Over 18MM US patients affected and >14MM prescriptions written for mild-to-moderate AD
- MM36 Phase 2 studies demonstrate strong competitive profile:
  - Fast and sustained itch relief
  - Stronger efficacy profile
  - Safe, well-tolerated and minimally absorbed

# Commercial Expertise

- *Expanding National Field Force in medical Dermatology*
  - Sales force approaching 40 strong in the highest potential markets
  - Wide breadth and depth across Dermatology and Podiatry
- *Commercial experts in creating, launching and maximizing brands*
  - Senior Management has long-standing and strong relationships with Key Opinion Leaders and High Volume Prescribers
- *Core brand Growth Drivers*

<b>Acne &amp; Rosacea</b>		<b>Skin &amp; Scalp Dermatoses</b>		<b>Onychodystrophy</b>	
<b>Clindacin®</b>	(clindamycin phosphate)	<b>Clodan®</b>	(clobetasol propionate)	<b>Genadur®</b>	(hydrosoluble nail lacquer)
<b>Neuac®</b>	(clindamycin/benzoyl peroxide)	<b>Neo-Synalar®</b>	(fluocinolone acetonide/neomycin)	<b>Inflammatory Skin Conditions</b>	
<b>Sumadan®</b>	(sodium sulfacetamide/sulfur)	<b>Synalar®</b>	(fluocinolone acetonide)	<b>Nicadan®</b>	(niacinamide)

# Atopic Dermatitis Portfolio

- **Synalar® Brand Franchise**

- *Synalar® has tremendous equity in Dermatology and is the foundation of Medimetriks' expertise in the atopic dermatitis (AD) market*

- *Brands: Synalar® Cream, Ointment, Topical Solution & Neo-Synalar® Cream*

- *Lead brand: Neo-Synalar®*

- *The only dual active steroid-antibiotic available for the treatment of steroid-responsive dermatoses with secondary infection*

- *S. aureus is present in >90% of adult patients with AD*


- *Potential first-line therapy for acute AD when infection is a concern*

- *Marketing exclusivity based on clinical/regulatory activities for dual-active formulation development, required clinical trials and ANDA approval timing*



# MM36: Blockbuster Pipeline Asset

- *Novel topical, non-steroidal PDE4 inhibitor for atopic dermatitis (AD) and itch*
  - *Phase 2 studies demonstrated rapid improvement of itch and objective signs of AD*
    - *Median time to **itch improvement of 5.8 hours** vs. Eucrisa® at 32.9 hours<sup>1</sup>*
    - *Subjects with moderate or severe disease achieved a 60% median reduction in itch by **hour 4***
  - *AD improvement in both EASI and IGA*
    - ***Clinically superior results** vs. vehicle and tacrolimus 1% (Protopic®)*
    - *Safe, well-tolerated (minimal application site reaction) and minimally absorbed*
- ***MM36** has potential to be a disruptive treatment in large, under-served AD and itch markets*
- *Preparing for Phase 3 trials*
- *Patent protection through 2033*



<sup>1</sup> Hebert, Eichenfeld, Lebwohl et al. Poster presented at Fall Clinical Dermatology Conference October 1-4, 2015, Las Vegas, NV

Note: Not head-to-head studies

# MM36: Mild-to-Moderate AD Market Opportunity

## Market Overview

- 18MM+ US patients affected by mild-to-moderate eczema with 14MM+ TRx written in the US
  - Safety is important as disease presents by age 5 in ~85% of cases
- Pfizer acquired Anacor Pharmaceuticals, developers of Eucrisa<sup>®</sup>, in June 2016 for US\$5.2 billion
  - Estimated peak US sales for Eucrisa<sup>®</sup> are >\$1.5B\*

## Unique Opportunity

- Atopic Dermatitis treated by a highly concentrated prescriber base in Dermatology, Pediatrics and select PCPs
- MM36 offers distinct advantages versus Eucrisa<sup>®</sup> and Protopic<sup>®</sup> based on MM36 early itch, efficacy and safety data

**MM36 has potential to be the best-in-class atopic dermatitis treatment**

\* Goldman Sachs Group, November 3, 2015

\*\* Symphony Health weekly TRx annualized and multiplied by current WAC, June 1, 2018